Research progress on asialoglycoprotein receptor-targeted radiotracers designed for hepatic nuclear medicine imaging

Eur J Med Chem. 2024 Feb 27;269:116278. doi: 10.1016/j.ejmech.2024.116278. Online ahead of print.ABSTRACTAsialoglycoprotein receptor (ASGPR) specifically recognizes glycans terminated with β-d-galactose or N-acetylgalactosamine. Its exclusive expression in mammalian hepatocytes renders it an ideal hepatic-targeted biomarker. To date, ASGPR-targeted ligands have been actively developed for drug delivery and hepatic imaging. This review provides a comprehensive summary of the progress achieved to-date in the field of developing ASGPR-targeted nuclear medicine imaging (NMI) radiotracers, highlighting the recent advancements over the last decade in terms of structure, radionuclides and labeling strategies. The biodistribution patterns, imaging characteristics, challenges and future prospective are discussed.PMID:38479165 | DOI:10.1016/j.ejmech.2024.116278
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research